How do you interpret the 5% absolute difference in 6-month locoregional failure between Q3 and weekly cisplatin seen in NRG-HN009 when counseling a patient with H&N SCC?
This question is part of our ASTRO 2026 collaboration, inspired by the LBA Session Presentation "NRG-HN009: A Randomized Phase II/III Trial of RT + Cisplatin (Q3 Weeks) vs. RT + Cisplatin (Weekly) for Oropharyngeal Cancer" by Dr. Paul Harari, MD, FASTRO
2 Answers
Mednet MemberInvited Expert
Radiation Oncology · Memorial Sloan Kettering Cancer Center
Answered on
At our center, we have not deviated from using Q3 weeks despite a strong push towards weekly by many, and this data reaffirms for us:
- No difference in tox between Q3 and weekly, contrary to what was suggested by others. That is true for both p16+ and negative.
- It is very concerning to see that at 6...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Radiation Oncology · University of Texas MD Anderson Cancer Center
Answered on
In his presentation, I noted 2 things:
- Dr. Harari did not seem concerned about the LRF at 6m and stated that, for the HPV- patients, the results were within the 8% predicted CI, and for the HPV+ patients, the results were within the 5% CI. While toxicity was the primary endpoint, it would have been...
Join for free or sign in to see the full answer